Point-of-care method for measuring infliximab and adalimumab trough levels in inflammatory bowel disease patients on biologic therapy
Original articleGastroent Hepatol 2022; 76(1): 35–41. doi: 10.48095/ccgh202235
SummaryLiteraturepdf Kristýna Kaštylová, Karin Černá , Štěpánka Luxová, Petr Šebek, Milan Lukáš